News | Heart Failure | November 21, 2019

Positive Results for SIRONA First-in-Human Trial of the Cordella PA Pressure Sensor System

Data presented at AHA 2019 showed positive impact on heart failure patients

The Cordella Pulmonary Artery Pressure Sensor System for Heart failure. #AHA19 #AHA

November 21, 2019 — Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), presented positive first-in-human data of the Cordella Pulmonary Artery (PA) Pressure Sensor System. Data was presented at the 2019 American Heart Association (AHA) scientific sessions by Prof. Dr. Wilfried Mullens of the Hospital Oost-Limburg in Genk, Belgium.

"Chronic heart failure patients too frequently have cycles of decompensation and hospitalization that negatively impact patient outcomes and drive up treatment costs. Recent data shows that using PA pressure-guided therapy with this population keeps them healthier and out of the hospital," Mullens explained. "The Cordella System is an elegant solution that integrates a PA pressure sensor and a comprehensive patient management platform in one. The straightforward sensor implant provides reliable pressure data, while the patient management platform enables a comprehensive clinical picture of the patient that allows my team to make informed therapy decisions and improve outcomes."

The 90-day results from the first-in-human trial confirm the device safety and accuracy of pressure measurements in the right pulmonary artery using the implanted Cordella Sensor and handheld patient reader. The study included 15 patients across two European sites: Mullens in Belgium and Dr. Faisal Sharif of the National University of Ireland (NUI) in Galway, Ireland.

 

SIRONA Trial Highlights

The primary accuracy endpoint was met with no significant difference in measured mean PA pressure for the Cordella Sensor and the reference catheter at 90 days.

The study demonstrated encouraging safety results with zero device related system complications (DSRC) at 90 days.

High patient compliance (>98%) with daily remote measurements of vital signs and PA pressure throughout the study.

"The presentation of our first-in-human data at AHA this year is another exciting milestone for the company," said Dr. Katrin Leadley, Chief Medical Officer of Endotronix. "This work lays the clinical foundation for our groundbreaking IDE trial, PROACTIVE-HF, which will begin enrollment in the U.S. later this year. Designed to provide the highest level of clinical evidence for PA pressure-guided therapy, PROACTIVE-HF will support U.S. market access of the Cordella Sensor and inform a national coverage decision from the Centers for Medicare & Medicaid Services (CMS)."

The Cordella Sensor is not available for commercial use in any geography and is under clinical investigation in Europe (SIRONA II CE Mark Trial) and the U.S. (PROACTIVE-HF IDE Trial). 

 

The Cordella Heart Failure System

The Cordella system is designed to help patients suffering from chronic heart failure feel better and stay out of the hospital with streamlined care and remote medication titration. The system provides a comprehensive health status of the patient at home with easy-to-use tools to securely collect and share health related data with healthcare providers for trend-based management. The Cordella Sensor seamlessly integrates pulmonary artery (PA) pressure data into the Cordella System. Together, they proactively deliver the information necessary to improve patient care between office visits and support reimbursement for care delivery activities.

For more information: www.endotronix.com

 

Find links to all the AHA late-breaking trials and other key news.

Related Content

Feature | AHA | By Dave Fornell, DAIC Editor

The following are the late-breaking science presentation sessions at the 2021 American Heart Association (AHA) 2021 ...

Home November 23, 2021
Home
News | AHA

September 20, 2021 — The American Heart Association (AHA) announced Sept. 16 it decided to convert from a planned in ...

Home September 20, 2021
Home
Feature | AHA | Dave Fornell, Editor

Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual ...

Home November 20, 2020
Home
News | AHA

July 15, 2020 – The last major cardiovascular conference to go virtual in 2020 due to the COVID-19 (SARS-Cov-2) pandemic ...

Home July 15, 2020
Home
News | AHA

November 22, 2019 — Artificial intelligence can examine electrocardiogram (ECG) test results, a common medical test, to ...

Home November 22, 2019
Home
News | AHA

November 21, 2019 — At the American Heart Association Scientific Sessions 2019, Eko, a digital health company applying ...

Home November 21, 2019
Home
News | AHA

November 21, 2019 — People who experience cardiac arrests over the weekend are less likely to survive long enough to be ...

Home November 21, 2019
Home
News | AHA

November 20, 2019 — Heart attack survivors may have an increased risk of developing cancer compared to people without ...

Home November 20, 2019
Home
News | AHA

November 20, 2019 — Ultra-processed foods, which account for more than half of an average American’s daily calories, are ...

Home November 20, 2019
Home
News | AHA

November 20, 2019 — Frequent cannabis (marijuana) use among young people was linked to an increased risk of stroke, and ...

Home November 20, 2019
Home
Subscribe Now